Clinical trial
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
NCT04018599
Study timeline
Study start (actual)2019-07-15Date precision: day
Registry last updated2020-03-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Rheumatoid Arthritisunresolved
Psoriatic Arthritisunresolved
Ankylosing Spondylitisunresolved
Crohn Diseaseunresolved
Ulcerative Colitisunresolved
Plaque Psoriasisunresolved
Pediatric Plaque Psoriasisunresolved
Pediatric Crohns Diseaseunresolved
Hidradenitis Suppurativaunresolved
Non-infectious Uveitisunresolved
Interventions
40 mg MSB11022DRUG
40 mg MSB11022DRUG
Sponsors & collaborators
Fresenius Kabi SwissBioSim GmbHlead sponsor
PRA Health Sciencescollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04018599 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.